Table. 2.

Serum HBV Markers Analysis from HBV-Transgenic Mice.

Treatmenta	HBV DNA (log10 ± SD)		HBsAg (%)	HBeAg (%)
	Day 20b	Day 20 – Baselinec	Day 20/Baselined	Day 20/Baselinee
Vehicle	8.44 ± 0.46	−0.04 ± 0.70n.s.	97.24 ± 9.75n.s.	96.17 ± 9.58n.s.
ETV(0.02 mg/kg)	6.09 ± 0.37	−2.55 ± 0.65*	98.62 ± 17.24n.s.	99.33 ± 12.03n.s.
6-AN(2.5 mg/kg)	6.87 ± 0.44	−1.83 ± 0.75*	64.82 ± 11.57⁎⁎	53.35 ± 16.25⁎⁎
6-AN(5 mg/kg)	6.37 ± 0.54	−2.43 ± 0.86*	57.50 ± 15.28⁎⁎	48.81 ± 12.49⁎⁎

At day 20, the levels of serum HBV DNA and the ratio of HBsAg from HBV-transgenic mouse was shown in Table 3 (n = 10 per group). (* P < 0.05, ^⁎⁎p < 0.01, n.s., not significant, compared with the vehicle group).

6-AN, 6-Aminonicotinamide; HBsAg, Hepatitis B surface antigen; HBeAg, Hepatitis B e antigen; ETV, Entecavir.

^aTreatment doses and schedules as described in the Methods section.

^bMean log₁₀ values ± standard error (copies/ml).

^cMean log₁₀ change values ± standard error (copies/ml) from baseline.

^dMean ratio values ± standard error (%) of HBsAg to baseline.

^eMean ratio values ± standard error (%) of HBeAg to baseline.